Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives
Frontiers in Medicine · 22.01.2025 · 12
DOI: 10.3389/fmed.2025.1535682 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Medicine, online erschienen am 22.01.2025. Verfasst von Virendra Kumar Yadav und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Sciences, Department of Microbiology, Marwadi University Research Center, Marwadi University, Rajkot, Gujarat, India. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 235 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Parkinson’s disease is a progressive neurodegenerative disease that destroys substantia nigra dopaminergic neurons, causing tremors, bradykinesia, rigidity, and postural instability. Current treatment approaches primarily focus on symptom management, employing pharmacological, non-pharmacological, and surgical methods. However, these treatments often result in fluctuating symptoms, side effects, and disease progression. Here, the authors have reviewed the emerging field of nanomedicine as a promising path for Parkinson’s disease treatment, emphasizing its potential to overcome the limitations of traditional therapies. Nanomedicine utilizes nanoparticles for targeted drug delivery, leveraging their small size and high surface area to volume ratio to cross the blood-brain barrier and deliver therapeutic agents directly to affected brain regions. Various nanoparticles, including lipid-based, polymeric, metallic, and carbon-based, have shown potential in Parkinson’s disease treatment. Additionally, nanocarrier systems like liposomes, nanogels, dendrimers, and solid lipid nanoparticles offer controlled and sustained release of therapeutic agents, enhancing their bioavailability and reducing side effects. This review provides insights into the pathophysiology of Parkinson’s disease, highlighting the mechanisms of neurodegeneration, the role of alpha-synuclein, and the disruption of dopaminergic pathways. It further discusses the application of gene therapy in conjunction with nanomedicine for targeted therapeutic interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Sciences, Department of Microbiology, Marwadi University Research Center, Marwadi University, Rajkot, Gujarat, India.
- Department of Computer Science, UiT The Arctic University of Norway, Tromsø, Norway.
- Department of Life Sciences, Parul Institute of Applied Sciences, Parul University, Vadodara, India.
- Department of Pharmacy Practice, NIMS Institute of Pharmacy, NIMS University Rajasthan, Jaipur, India.
- Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, India.
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, India.
Zitieren
APA
Yadav, V. K., Dhanasekaran, S., Choudhary, N., Nathiya, D., Thakur, V., Gupta, R., Pramanik, S., Kumar, P., Gupta, N., & Patel, A. (2025). Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives. Frontiers in Medicine, 12. https://doi.org/10.3389/fmed.2025.1535682
Vancouver
Yadav VK, Dhanasekaran S, Choudhary N, Nathiya D, Thakur V, Gupta R, et al. Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives. Frontiers in Medicine. 2025;12. doi:10.3389/fmed.2025.1535682
BibTeX
@article{Yadav2025,
author = {Yadav, Virendra Kumar and Dhanasekaran, Seshathiri and Choudhary, Nisha and Nathiya, Deepak and Thakur, Vishal and Gupta, Rachna and Pramanik, Sheersha and Kumar, Pankaj and Gupta, Nishant and Patel, Ashish},
title = {Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives},
journal = {Frontiers in Medicine},
year = {2025},
volume = {12},
doi = {10.3389/fmed.2025.1535682}
}
EUVIMED